Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omicron BA.4/5-Delta Recombinant Protein Vaccine Phase I
NCT06043388Phase 1Not yet recruiting
- Sponsor
- Zhifei Biological
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of Omicron BA.4/5-Delta recombinant protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zhifei Biological. Primary endpoint: Safety endpoint at 12 months. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
Omicron BA.4/5-Delta recombinant protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06043388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043388.